---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Budget impact"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Budget impact. Topics: Summary: price status, comparator costs, and costs of uncontrolled hypertension; Summary: ICER cost-effectiveness and health-benefit price benchmark; Summary: ICER potential budget impact, other economic evaluations, and forecasts. 3 evidence topics quoted from 23 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary/budget-impact"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Budget impact

<a id="heading-1.1.3"></a>

## 1.1.3 Budget Impact of Lorundrostat

<a id="topic-1.1.3-1"></a>

### Summary: price status, comparator costs, and costs of uncontrolled hypertension

Lorundrostat has no announced price. On its third quarter 2026 earnings call, Mineralys stated that “we haven't finalized the price yet” and that it would communicate pricing, access, and gross to net information “sometime post approval, post launch”. On its fourth quarter 2025 earnings call, the company described its pricing frame as “more of an SGLT2-branded price point, Entresto price point, broadly at a WAC” and stated that it had “not guided as it relates to rebates”. No estimate of monthly and annual cost is given, because lorundrostat is not approved and no price has been published.

The Institute for Clinical and Economic Review (ICER) costed lorundrostat 50 mg once daily at a placeholder price equal to the baxdrostat wholesale acquisition cost (WAC) from RedBook ($900 for 30 tablets), or $30 per dose and $10,950 per year; for baxdrostat, ICER used the WAC as the net price because no information was available to inform a discount. For the generic comparators, ICER used the median WAC across generic versions: $43 to $171 per year for spironolactone (25 to 100 mg), $511 to $1,022 per year for eplerenone (50 to 100 mg), and $206 to $411 per year for amiloride (5 to 10 mg). The National Average Drug Acquisition Cost (NADAC) effective 18 November 2026 was $28.78424 per BAXFENDY 2 mg tablet, $0.04218 per spironolactone 25 mg tablet, $0.47438 per eplerenone 50 mg tablet, and $0.20688 per amiloride 5 mg tablet.

In a US claims cohort of 3,966 individuals with stage 3 to 4 chronic kidney disease using three or more antihypertensive drugs, uncontrolled blood pressure was associated with $10,055 higher total medical and pharmacy costs per patient per year than controlled blood pressure. A review estimates that apparent resistant hypertension increases US health care expenditures by $11 billion to $18 billion per year over non-resistant hypertension. ICER's model applied annual health state costs of $3,211 for hypertension and $108,953 for end-stage kidney disease.

Source: [Mineralys Therapeutics third quarter 2026 earnings call transcript (2026)](https://www.tradingkey.com/news/transcripts/262279607-); [Mineralys Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/03/12/mineralys-mlys-q4-2025-earnings-call-transcript); [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf); [ICER public meeting slides (2026)](https://icer.org/wp-content/uploads/2026/03/ICER_Hypertension_Public-Meeting-Slides_102926_For_Publication.pdf); [CMS NADAC, BAXFENDY 2 mg (2026)](https://data.medicaid.gov/api/1/datastore/query/fbb83258-11c7-47f5-8b18-5f8e79f7e704/0?conditions[0][property]=ndc&conditions[0][value]=00310600230&conditions[0][operator]==&conditions[1][property]=effective_date&conditions[1][value]=2026-11-18&conditions[1][operator]==&limit=1); [CMS NADAC, spironolactone 25 mg (2026)](https://data.medicaid.gov/api/1/datastore/query/fbb83258-11c7-47f5-8b18-5f8e79f7e704/0?conditions[0][property]=ndc&conditions[0][value]=53489014310&conditions[0][operator]==&conditions[1][property]=effective_date&conditions[1][value]=2026-11-18&conditions[1][operator]==&limit=1); [CMS NADAC, eplerenone 50 mg (2026)](https://data.medicaid.gov/api/1/datastore/query/fbb83258-11c7-47f5-8b18-5f8e79f7e704/0?conditions[0][property]=ndc&conditions[0][value]=31722005030&conditions[0][operator]==&conditions[1][property]=effective_date&conditions[1][value]=2026-11-18&conditions[1][operator]==&limit=1); [CMS NADAC, amiloride 5 mg (2026)](https://data.medicaid.gov/api/1/datastore/query/fbb83258-11c7-47f5-8b18-5f8e79f7e704/0?conditions[0][property]=ndc&conditions[0][value]=42794000502&conditions[0][operator]==&conditions[1][property]=effective_date&conditions[1][value]=2026-11-18&conditions[1][operator]==&limit=1); [Bakris et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11094384/); [Flack et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11533979/)

<a id="topic-1.1.3-2"></a>

### Summary: ICER cost-effectiveness and health-benefit price benchmark

ICER assessed baxdrostat and lorundrostat in a 2026 evidence report discussed at the “Midwest CEPAC 2026 public meeting on aldosterone synthase inhibitors for hypertension”. The assessment page lists a “Final Evidence Report and Meeting Summary”, and the meeting slides state that the final report would be published “on or around November 30, 2026”; the figures below are from the evidence report. ICER rated the evidence “insufficient” to distinguish the net health benefits of lorundrostat and baxdrostat, rated either drug “Promising but Inconclusive” compared with spironolactone, eplerenone, or amiloride in Population 1 (resistant hypertension not at goal) and Population 2 (not at goal on two drugs after not tolerating a third), and rated either drug “comparable or inferior” to amlodipine in Population 3.

ICER's de novo model took a US health care sector perspective over a lifetime horizon, with costs and outcomes discounted at 3% per year and three-month cycles. Populations 1 and 2 were modeled as one population, and Population 3 was not modeled. Lorundrostat was modeled at 50 mg once daily and at the placeholder price of $10,950 per year. Lifetime total costs were $150,700 with lorundrostat against $122,800 with spironolactone, $124,300 with eplerenone, and $123,400 with amiloride, with 9.54 QALYs against 9.52, 9.54, and 9.52. The incremental cost-effectiveness ratio for lorundrostat was $1,419,000 per QALY gained compared with spironolactone and $1,492,000 per QALY gained compared with amiloride. Compared with eplerenone, lorundrostat was “More costly, less effective”, which ICER attributed to a first-cycle discontinuation probability of 10% for lorundrostat (from Launch-HTN) against 7.7% for eplerenone. Baxdrostat at its WAC had ratios of $833,000, $2,077,000, and $851,000 per QALY gained compared with spironolactone, eplerenone, and amiloride. In probabilistic analyses, lorundrostat was cost-effective in 0.0% of simulations at $150,000 per evLY gained against each comparator and in 0.2% at $200,000 per evLY gained against eplerenone and amiloride. In the modified societal perspective scenario, its ratios were $1,404,000 per QALY gained compared with spironolactone and $1,479,000 compared with amiloride, and ICER stated that the ratios in the modified societal and same-discontinuation scenarios were “still well above commonly accepted threshold ranges”.

The health-benefit price benchmark, the price range that achieves $100,000 per QALY gained to $150,000 per evLY gained, was $760 to $1,600 per year for lorundrostat, a discount from the placeholder price of 86.3% to 93.0% on the QALY basis and 85.7% to 93.0% on the evLY basis, and $1,400 to $2,500 per year for baxdrostat.

In public comments, Mineralys stated that the model “does not fully capture the clinical and economic benefits of ASIs”, recommended removing amiloride and eplerenone as comparators, noted that the 7.7% discontinuation rate for eplerenone and amiloride came from a study of Swedish patients receiving calcium channel blockers, and recommended dynamic pricing. ICER responded that it tested several discontinuation scenarios and “none changed our conclusion”, and that it does not as a rule consider dynamic pricing without known timing for patent expiry. The coalition No Patient Left Behind estimated a societal value-based price for lorundrostat of $18,767 per year (base case) to $26,913 per year (optimistic case).

Source: [ICER hypertension assessment page (2026)](https://icer.org/assessment/hypertension-2026/); [ICER public meeting slides (2026)](https://icer.org/wp-content/uploads/2026/03/ICER_Hypertension_Public-Meeting-Slides_102926_For_Publication.pdf); [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf); [ICER public comment folio (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_Public-Comment-Folio_100126.pdf); [ICER response to public comments (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_Public_Comment_Grid-For-Publication-102626.pdf)

<a id="topic-1.1.3-3"></a>

### Summary: ICER potential budget impact, other economic evaluations, and forecasts

ICER's potential budget impact analysis is the only budget impact analysis of lorundrostat identified. It calculated health care costs, including drug costs, minus offsets from averted health care events, undiscounted over five years, against an even split of spironolactone, eplerenone, and amiloride, with 20% uptake in each year. Population 1 was sized from a hypertension prevalence of 48.1% among US adults, 51.2% of those with hypertension taking medication, and 15% of those taking medication treated with three or more drugs and uncontrolled, applied to 271,862,765 adults: 10,042,828 eligible patients, or 2,008,565 initiating treatment per year. Population 2 (17.9% treated with two drugs and uncontrolled, of whom 21% were assumed, as a “placeholder estimate”, to have tried and discontinued a third) comprised 2,516,732 patients, or 503,346 per year, for a total of 12,559,560 eligible patients. ICER did not estimate the budget impact for Population 3. At the placeholder price of $10,950 per year, the cumulative budget impact per patient was approximately $8,500 in year one and $16,300 by year five (baxdrostat: $8,300 and $15,700), and approximately 2% of eligible patients could be treated before reaching ICER's potential budget impact threshold of $821 million per year. At threshold prices, 100% of eligible patients could be treated compared with eplerenone at every threshold, and compared with spironolactone ($630) and amiloride ($810) at $50,000 per evLY gained; at $200,000 per evLY gained, approximately 17% (spironolactone, $1,800) and 15% (amiloride, $1,900) could be treated. ICER reports national figures; a 2026 poster hosted by Mineralys estimates, for a hypothetical 1 million–member US health plan, 194,140 adults diagnosed and treated for hypertension, 104,494 (53.8%) with uncontrolled hypertension, and 37,081 receiving three or more antihypertensive drugs. Mineralys describes its initial target population as “third line or later”.

No published cost-effectiveness analysis of lorundrostat other than ICER's was identified, and a 2026 review states that aldosterone synthase inhibitors need “evidence of cost-effectiveness”. No published cost-effectiveness analysis of spironolactone, eplerenone, amiloride, or aprocitentan for resistant hypertension was identified. A 2026 systematic review found 21 modelling studies in treatment-resistant and uncontrolled hypertension, and 12 of its 14 cost-utility analyses evaluated renal denervation. Published analyses report $32,732 per QALY for radiofrequency renal denervation (Medicare payer perspective, lifetime horizon), $12,900 per QALY for ultrasound renal denervation (US health care system perspective, lifetime horizon, procedure cost $23,000), $3,071 per QALY in a 2012 societal-perspective model in resistant hypertension, $4,400 per QALY gained for team-based care with non-physician medication titration at 10 years, and cost savings of $10,162 per person for pharmacist prescribing.

GlobalData forecast lorundrostat sales of $601 million in 2030. Visible Alpha consensus assigns lorundrostat a 90% probability of US approval, with risk-adjusted sales of $122 million in 2027 and $365 million in 2028, and projects higher sales for baxdrostat than for lorundrostat over the remainder of the decade; the same report states that analysts expect annual revenue of $1.1 billion by 2030.

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf); [Henry et al. (2026)](https://mineralystx.com/wp-content/uploads/2026/11/ISPOREurope26_Henry_EPH1_POSTER.pdf); [Mineralys Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/03/12/mineralys-mlys-q4-2025-earnings-call-transcript); [Baker (2026)](https://pubmed.ncbi.nlm.nih.gov/42847224/); [Franklin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13375916/); [Kandzari et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11549517/); [Taylor et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12230492/); [Geisler et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22981547/); [Bryant et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10987007/); [Dixon et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10625044/); [Beaney (2025)](https://www.clinicaltrialsarena.com/news/mineralys-therapeutics-stock-jumps-hypertension-trial-data/); [S&P Global Market Intelligence (2026)](https://www.spglobal.com/market-intelligence/en/news-insights/research/2026/07/astrazeneca-s-baxfendy-set-for-blockbuster-sales-after-hypertension-approval)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
